Applied BioMath, Syntimmune collaborate onautoimmune diseases

Monday, December 4, 2017

Applied BioMath, a provider in applying mechanistic modeling to drug research and development, announced a collaboration with Syntimmune to provide semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling for Syntimmune’s ongoing clinical trials. Applied BioMath will deploy its Model-Aided Drug Invention (MADI) to analyze clinical data from Syntimmune’s lead drug candidate, SYNT001. The goal is to create a semi-mechanistic PK/PD model to support further advancement of Syntimmune’s clinical trials of SYNT001 in a broad variety of IgG-mediated autoimmune diseases, including ongoing trials in Warm Autoimmune Hemolytic Anemia, Pemphigus, and other clinical indications.

[Read More]

Syntimmune appoints David De Graaf CEO

Friday, November 18, 2016

Syntimmune, a clinical-stage biotechnology company advancing novel treatments for IgG-mediated autoimmune diseases based on leading expertise in FcRn biology, has announced the expansion of its leadership team and Board of Directors. David de Graaf, Ph.D. has been appointed Syntimmune’s president and chief executive officer, and Burt Adelman, M.D. has been elected to the company’s board and named as senior advisor to the company.

[Read More]